Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CNV 2197944

Next Previous
Drug Profile

CNV 2197944

Alternative Names: CNV-2197944

Latest Information Update: 02 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Calchan
  • Class Analgesics; Small molecules
  • Mechanism of Action N-type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Postherpetic neuralgia
  • No development reported Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain(In volunteers) in United Kingdom (PO)
  • 30 Jun 2014 Convergence Pharmaceuticals completes a phase II trial in Diabetic neuropathies in Hungary, Czech Republic, Bulgaria & Poland (NCT01893125) (EudraCT2013-000407-16)
  • 06 Feb 2014 Convergence Pharmaceuticals completes a phase II trial in Postherpetic neuralgia in Bulgaria and South Africa (NCT reference)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top